cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Editor PSR
Contact Email
article@farmasi.ui.ac.id
Phone
+62-21-27608403
Journal Mail Official
psr@farmasi.ui.ac.id
Editorial Address
3rd Floor, A Building, Rumpun Ilmu Kesehatan Kampus Baru UI Depok, 16424, Indonesia
Location
Kota depok,
Jawa barat
INDONESIA
Pharmaceutical Sciences and Research (PSR)
Published by Universitas Indonesia
ISSN : 24072354     EISSN : 24770612     DOI : https://doi.org/10.7454/psr
Core Subject :
Aims Pharmaceutical Sciences and Research (PSR), an international, peer-reviewed, open access, and official journal from Faculty of Pharmacy, Universitas Indonesia, aims to disseminate research results and findings in Pharmaceutical Sciences and Practices. Major area of interest is natural products in drug discovery and development. We also consider other areas related to pharmaceutical sciences and practices. PSR publishes content in English language to promote the sharing of knowledge to international scholars. PSR publish 5 types of articles: 1. Original article 2. Case report 3. Case series 4. Review article 5. Mini review article Scope Researches in Pharmaceutical Sciences and Practices which are covered by PSR are within these subject areas: - Pharmacognosy and Phytochemistry - Pharmaceutical Chemistry - Pharmaceutical Technology - Pharmaceutical Biotechnology - Clinical Pharmacy - Pharmacology-Toxicology - Social and Administrative Pharmacy, including Pharmacoeconomy
Arjuna Subject : -
Articles 355 Documents
 32   33   34   35   36 
In vitro Antiviral Activity of Cat’s Claw (Uncaria tomentosa) bark Extract Against Human Influenza A Virus Makau, Juliann N; Talaam, Keith K; Odiwuor, Mike; Majanja, Janet M; Musenjeri, Sophia; Rahmasari, Ratika; Khamadi, Samoel A; Watanabe, Ken
Pharmaceutical Sciences and Research Vol. 12, No. 2
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Influenza A viruses mutate very fast and this leads to the development of resistance to antivirals, hence the need to find new therapeutics. Due to their extensive traditional use, natural products are crucial resources for the discovery of drugs. Cat’s claw (Uncaria tomentosa), is a tropical vine known for various health benefits and in this study we evaluated its anti-influenza activity. Pulverized material of the stem bark was extracted using 80% ethanol, hot water, and 1% sodium bicarbonate. The extracts were dried and dissolved in dimethylsulfoxide before testing for cytotoxicity and antiviral activity using crystal violet assay. The extracts exhibited antiviral activity with a 50% inhibitory concentration range of 2.3 - 6.2 µg/mL. The 1% sodium bicarbonate extract had the least 50% cytotoxic concentration of 125 µg/mL and was used for further analyses. It was effective against several human influenza A virus strains including an oseltamivir-resistant clinical isolate of the 2009 H1N1 pandemic influenza. Time-of-addition experiments showed significant suppression of virus replication when the virus was pretreated with the extract before infecting to cells and also when the virus and extract were co-administered to the cells; suggesting that the extract was inactivating the virus. Oseltamivir was used as a positive control and only suppressed late stages of virus replication. These results were consistent with the hemagglutination inhibition assay data which showed direct virucidal activity on influenza virus particles. Our data demonstrates possible future use of Cat’s claw in influenza management. However, more investigation is needed to identify the bioactive components.
Exploring The Vitronectin Binding Affinity and Cell Viability Effect of Small Molecule Metabolites From Medicinal Plants For Neuroblastoma Alaribe, Stephenie C. A; Granados-Aparici, Sofia; Oladipupo, Akolade R; Vieco-Marti, Isaac; Titilayo, Blessing E; Allen, Gordon; Noguera, Rosa
Pharmaceutical Sciences and Research Vol. 12, No. 2
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

High-risk neuroblastoma (HR-NB) is an aggressive form of childhood cancer with a five-year survival rate of less than 50%, underscoring the need for more efficacious and less toxic treatments. The glycoprotein vitronectin (VN) has been linked to poor prognosis in patients with HR-NB, thus inhibitors of VN function represent a promising avenue for molecular mechanotherapy. This study investigated the binding affinity between the somatomedin B (SMB) domain of VN and natural compounds from the medicinal plant, Olax subscorpioidea, targeting the plasminogen activator inhibitor-1 (PAI-1). The therapeutic potential of α-amyrin (AMY), lupeol (LUP), and olax chalcone A (olax CHA) was tested in combination with an integrin antagonist of VN, cilengitide (CLG), using the SK-N-BE(2) HR-NB cell line as a model. Molecular docking studies indicated protein-ligand interactions for all compounds, with CLG showing the most favorable binding free energy, followed by LUP, AMY, and olax CHA. Molecular dynamics simulations indicated the SMB domain of VN binding site of PAI-1 initially exhibited flexibility, with alpha-carbon root mean square deviation (RMSD) stabilizing at 1.8-2.1 Å. All compounds reduced SK-N-BE(2) cell viability in a dose-dependent manner. CLG showed the strongest antiproliferative effect (IC₅₀ = 15.25 µM). Olax CHA had higher efficacy than AMY and LUP (IC₅₀ = 74.23 µM vs. 125.45 µM and 103.36 µM). Combining the compounds with CLG further decreased viability and IC₅₀ values. Synergy analysis showed only olax CHA plus CLG had a synergistic effect. This suggests olax CHA plus CLG as a promising therapeutic strategy against neuroblastoma cells.
Efficacy and Safety of Glibenclamide Compared with Insulin in Gestational Diabetes Mellitus: A Systematic Review and Meta-analysis Haifa, Alifia Fauziyyah; Qomariyanti, Khairunnisa; Sartika, Ratu Ayu Dewi; Sauriasari, Rani
Pharmaceutical Sciences and Research Vol. 12, No. 2
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Gestational diabetes mellitus (GDM) is a prevalent pregnancy complication associated with an increased risk of maternal and neonatal complications compared with non-diabetic pregnancies. Pharmacological treatments, such as glibenclamide, are expected to provide optimal glycemic control and reduce these risks. However, concerns regarding its safety persist and some regulatory agencies have not approved glibenclamide for GDM treatment. This systematic review and meta-analysis aimed to synthesize the most recent evidence on the efficacy and safety of glibenclamide compared with insulin in the management of GDM, with a focus on maternal and neonatal outcomes based on the most recent RCT. The objective is to provide updated insight and strengthen the evidence based supporting the use of glibenclamide as treatment option for GDM. Relevant studies were identified from Pubmed, Scopus, and CENTRAL databases, resulting in 11 randomized controlled trials (RCTs) involving 2,019 participants. The pooled analysis found that glibenclamide significantly increases the risk of neonatal hypoglycemia [RR 1.65; 95% CI 1.23 to 2.22; p-value 0.0009] and significantly decreases the risk of neonatal respiratory distress syndrome (NRDS) [RR 0.56; 95% CI 0.33 to 0.95; p-value 0.03], compared to insulin. No significant differences were observed in other maternal and neonatal outcomes between the two treatments. In conclusion, glibenclamide demonstrated comparable efficacy and safety to insulin in the management of GDM, making it a viable treatment option alongside insulin.
Advancing Herbal Medicine: The Role of Nanosomal Technology in Treating Skin Diseases Aswan, Pedro Anugerah; Maggadani, Baitha Palanggatan; Fachri, Wilzar; Iswandana, Raditya
Pharmaceutical Sciences and Research Vol. 12, No. 2
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Herbal medicine has become popular worldwide, especially in developing countries, with around 80% of the population opting for herbal treatments. The perceived benefits of natural remedies, such as affordability and fewer side effects, drive this trend. Herbal therapies effectively manage skin diseases, infections, and common ailments. However, the absorption of bioactive compounds in herbal extracts is often limited. Recent developments in nano-based herbal delivery systems, like nanosomal, show promise in enhancing the efficacy of herbal remedies for topical applications, providing improved solubility, stability, and skin penetration. This review describes various nanosomal studies developed and successfully used to enhance the topical delivery of natural compounds, including liposomes, ethosomes, transfersomes, transethosomes, phytosomes, and niosomes.
In-Silico Test of Myricetin, Phyllanthin, Luteolin Compounds Against SARS-CoV-2 Proteins Noviyanti, Vidia; Arifin, Nuha Haifa; Ikfini, Hayu; Febriansah, Rifki
Pharmaceutical Sciences and Research
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Coronavirus disease 2019 (COVID-19), which emerged in late 2019 and was first detected in Indonesia in March 2020, has significantly reshaped the country’s public health landscape. Aside from the viral outbreak itself, a decline in immunity among the population due to excessive concern about the pandemic has also become a significant issue. This study aimed to evaluate the potential of myricetin, phyllanthin, and luteolin compounds as inhibitors of the SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) virus by targeting the main protease and spike glycoprotein receptor-binding domain proteins through in silico molecular docking. Remdesivir and favipiravir were used as comparison compounds. The molecular docking process involved several stages including structural preparation, protein preparation, method validation, and docking between the compounds with the target protein. The docking results were assessed based on binding energy values, where lower energy indicates a stronger and more stable interaction between the compound and the protein. The binding energies of myricetin, phyllanthin, luteolin, favipiravir and remdesivir compounds with the main protease protein were -6.2, -5.5, -5.3, -4,4, and -5.5 kcal/mol, respectively. The binding energies of those compounds with spike glycoprotein-RBD were -6.0, -4.2, -4.8, -6.0, and -5.3 kcal/mol, respectively. The results showed that myricetin exhibited stronger binding affinity compared to phyllanthin and luteolin and may serve as a promising inhibitor of main protease and spike glycoprotein receptor-binding domain proteins.

Page 36 of 36 | Total Record : 355

 32   33   34   35   36 

Filter by Year

2004 2025


Reset
Filter By Issues
All Issue Vol. 12, No. 2 Vol. 12, No. 1 Vol. 11, No. 3 Vol. 11, No. 2 Vol. 11, No. 1 Vol. 10, No. 3 Vol. 10, No. 2 Vol. 10, No. 1 Vol. 7, No. 4 Vol. 9, No. 3 Vol. 9, No. 2 Vol. 9, No. 1 Vol. 8, No. 3 Vol. 8, No. 2 Vol. 8, No. 1 Vol. 7, No. 3 Vol. 7, No. 2 Vol. 7, No. 1 Vol. 6, No. 3 Vol. 6, No. 2 Vol. 6, No. 1 Vol. 5, No. 3 Vol. 5, No. 2 Vol. 5, No. 1 Vol. 4, No. 3 Vol. 4, No. 2 Vol. 4, No. 1 Vol. 3, No. 3 Vol. 3, No. 2 Vol. 3, No. 1 Vol. 2, No. 3 Vol. 2, No. 2 Vol. 2, No. 1 Vol. 1, No. 3 Vol. 1, No. 2 Vol. 1, No. 1 More Issue